Lv1
24 积分 2023-09-19 加入
New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide
5天前
已完结
New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide
5天前
已完结
Mechanistic evaluation of the initial burst release of leuprolide from spray-dried PLGA microspheres
5天前
已完结
In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system
5天前
已关闭
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients
7天前
已完结
New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide
8天前
已完结
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
8天前
已完结
Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system
16天前
已完结
A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer
16天前
已完结
The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review
17天前
已完结
皖公网安备34019202002308
